The aim of the study was to provide a detailed apolipoproteic profile in stage II peripheral vascular disease (PVD) patients and to ascertain whether lower ankle/ arm pressure index (API) values were associated with a worse profile.
Apolipoproteins of 83 stage II PVD patients (average age 64.7 ± 9.3 years) were selected and compared with those of a group of 44 normal control subjects, similar in terms of age, sex, and smoking and eating habits. Neither PVD patients nor controls had ever received lipid-lowering agents or defined dietary treatment. A diagnosis of PVD was confirmed by an API of <0.85. Arteriopathic patients were also split into two groups, depending on their API values, similar in terms of age, sex and smoking habits: API values of one group (n = 38) were ≥0.6, those of the other group (n = 45) were <0.6. The following biohumoral parameters were considered: fasting glycemia, total cholesterol, triglycerides (TGs); high-density lipoprotein cholesterol (HDL-C); low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), total cholesterol (TC)/HDL-C (TC/ HDL-C), Apoproteins (Apos) AI, AII, B, CII, CIII, and E; and lipoprotein a [Lp(a)].
HDL-C and Apo AI were lower (p < 0.01), while TC/ HDL-C ratios, Apo B, and Apo CII were higher (p < 0.01) in PVD patients compared with controls. The comparison between the two PVD groups with different API values showed higher blood TG and VLDL-C values for the patients with lower API values (p < 0.05), indicating a relationship between hypertriglyceridemia and greater arterial damage. Key Words: Peripheral arterial occlusive disease-Triglyceride-Lipoprotein a.
Get full access to this article
View all access options for this article.
References
1.
Gordon T., Kannel WBPredisposition to atherosclerosis in the head, heart, and legs: theFramingham Study. JAMA1972;221:661-6.
2.
Pomrehn P., Duncan B., Weissfeld L., et al. The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease: the Lipids Research Clinics Program prevalence study. Circulation1986;73(suppl I):100-7.
3.
Johansson J. , Egberg N., Johnsson H., Carlson LASerum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb1993;13:1441-8.
4.
Gordon T., Castelli WP, Hjortland MC, Kannel WB, Dawber TRHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977:62:707-14.
5.
Miller NE, Forde OH, Thelle DS, Mjos ODThe Tromso Heart Study: high density lipoprotein and coronary heart disease: a prospective case-control study. Lancet1977 ;1: 965-70.
6.
Goldbourt U. , Medalie JHHigh density lipoprotein cholesterol and incidence of coronary heart disease: the Israeli Ischaemic Heart Disease Study. Am J Epidemiol1979;109: 296-308.
7.
Enger SC, Hjermann I., Foss OP, et al. High density lipoprotein cholesterol and myocardial infarction and sudden coronary death: a prospective case-control study in middle-aged men of the Oslo Study. Artery1979;5:170-81.
8.
Keys A.Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death. Lancet1980;2:603-6.
9.
Baker G., Rosseneu M., Deslypere JPDiscriminative value of lipids and apoproteins in coronary heart disease . Atherosclerosis1982;42:197-203.
10.
Maciejko JJ , Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao Sjt.Apoprotein AI as a marker of angiographically assessed coronary artery disease. N Engl J Med1983; 309:385-9.
11.
Keys A., Karvonen MH, Punsar S., Menotti A., Fidanza F., Farchi G.HDL serum cholesterol and 24-year mortality of men in Finland. Int J Epidemiol1984;13:428-35.
12.
Goldbourt U., Holtzman E., Neufeld HNTotal and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of threshold effect. Br Med J1985;290:1239-43.
13.
Jacobs DR (for the Lipid Research Clinics Follow-up Study). High density lipoprotein cholesterol and coronary heart disease, cardiovascular disease, and all-cause mortality [Abstract]. Circulation1985;72(suppl III):85.
14.
Watkins LO, Neaton JD, Kuller LH (for the MRFIT Research Group). Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the Usual Care Group of the Multiple Risk Factor Intervention Trial. Am J Cardiol1986;57:338-45.
15.
Castelli VP , Garrison RJ, Wilson Pwf, Abbott RD, Kalousdian S., Kannel WBIncidence of coronary heart disease and lipoprotein levels: the Framingham Study. JAMA1986;256: 2835-8.
16.
Gordon DJ, Knoke J., Probstfield GL, Superko R., Tyroler HA (for the Lipid Research Clinics Program). High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation1996;74:1217-25.
17.
Steinberg D.Lipoproteins and the pathogenesis of atherosclerosis . Circulation1987;76:508-41
18.
Scott Grundy M.Multifactorial etiology of hypercholesterolemia . Implications for the prevention of Coronary Heart Disease. Arterioscler Thromb1991;11:1619-35.
19.
Pilger E., Pristauz H., Pfeiffer KP, Kostner G.Risk factors for peripheral atherosclerosis. Retrospective evaluation by stepwise discriminant analysis. Arteriosclerosis1983 ;3:57-63.
20.
Stokes J., Kannel WB, Wolf PA, Cupples LA, D'Agostino RBThe relative importance of selected risk factor for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation1987;75(suppl V):65-73.
21.
Wiseman SA, Powell JT, Barber N., Humphries SE, Greenhalgh RMInfluence of apolipoproteins on the anatomical distribution of arterial disease . Atherosclerosis1991;89: 321-7.
22.
Sacco RL, Wolf PA, Kannel WB, Mc Namara PM.Survival and recurrence following stroke: the Framingham Study, Stroke1982;13:290-5.
23.
Alter M. Sobel E., McCoy R., et al. Stroke in the Lehigh Valley: risk factors for recurrent stroke. Neurology1987 ;37: 503-7.
24.
Welin L., Svardsudd K., Wlheelmsen L., Larsson B., Tibblin G.Analysis of risk factors for stroke in a cohort of men born in 1913 . N Engl J Med1987;317:521-6.
25.
Boysen G., Nyboe J., Aappleyard M., et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke1988;19:1345-53.
26.
Hier DB, Foulkes MA, Swintoniowski M., et al. Stroke recurrence within 2 years after ischemic infarction. Stroke1991;22:155-61.
27.
Wolf P., Cobb J., D'Agostino R.Epidemiology of stroke. In: Barnett HJ, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, diagnosis, and management. 2nd ed. New York : Churchill Livingstone , 1992:3-27.
28.
Suurkula M. , Agewall S., Fagerberg B., Wendelhag I., Widgren B., Wikstrand J.Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high-risk hypertensive patients. Arterioscfer Thromb1994;14:1297-304.
29.
Alter M., Friday G., Lai SM, O'Connel J., Sobel E.Hypertension and risk of stroke recurrence. Stroke1994;25:1605-10.
30.
Feinberg WM , Albers GW, Barnett Hjm, et al. Guidelines for the management of transient ischemic attacks. From the Ad Hoc Committee on guidelines for the management of transient ischemic attacks of the stroke council of the American Heart Association. Stroke1994;25:1320-35.
31.
Lai SM, Alter M., Friday G., Sobel E.A multifactorial analysis of risk factors for recurrence of ischemic stroke . Stroke1994;25:958-62.
32.
Fowkes Fgr.Actiology of peripheral atherosclerosis. Br Med J1989;298:405-6.
33.
Meerloo JM, Billimoria JDHigh density lipoprotein cholesterol levels in peripheral vascular disease and in women on oral contraception. Atherosclerosis1977;33:267-71.
34.
Bihari-Vargi M., Szekeley J., Gruber E.Plasma high density lipoproteins in coronary, cerebral and peripheral vascular disease: the influence of various risk factors . Atherosclerosis1981;40:337-45.
35.
Senti M., Nogues X., Pedro-Botet J., Prat JR, Barraquer FVLipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation1992;85:30-6.
36.
Franceschini G., Bondioli A., Mantero M., et al. Increased apoprotein B in very low density lipoproteins of patients with peripheral vascular disease . Arteriosclerosis1982;2:74-80.
37.
Winsor T.Influence of arterial disease on the systolic blood pressure gradients of the extremity. Am J Med Sci1950;220: 117-26.
38.
Carter SAIndirect systolic pressure and pulse waves in arterial occlusive of the lower extremities. Circulation1968; 37:624-38.
39.
Yao STNew techniques of objective arterial evaluation. Arch Surg1973;106:600-4.
40.
Fowkes Fgr.The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol1988;17:248-54.
41.
Roschlau P. , Bemt E., Cruber W.Enzymatische bestimmung der gesamtecholesterins in serum. Chem Klin.Biochem1974; 12:226-7.
42.
Wahlefeld AW , Bergmeyer HUMethoden der enzymatischen. Analyse, 3 ed., Vol II. Weinheim: Verlag Chemie, 1974, 1878.
43.
Lopez-Virella MF, Stone J., Ellis Golwell JACholesterol determination in high density lipoproteins separated by three different methods. Clin Chem1977;23:882-4.
44.
Mancini G., Carbonara OA, Heremans JFImmunochemical quantitation of antigens by single radial immunodiffusion . Immunochemistry1965;2:235-54.
45.
Berg K.A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand1963;59:369-82.
46.
Giacherio D. , Matz K.Evaluation of an enzyme immunoassay kit for the determination of lipoprotein(a). Clin Chem1990;36:955a.
47.
Criqui MH, Browmer D., Fronek K., et al. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease. Am J Epidemiol1989;129:1110-9.
48.
Assman G., Schmitz G., Funke H., Von Eckardstein A.Apolipoprotein Al and HDL deficiency. Curr Opin Lipodol1990; 1:110-5.
49.
Editorial. Cholesteryl ester transfer protein. Lancet1991 ; 338:666-7.
50.
Durrington PNHow HDL protects against atheroma. Lancet1993;342:1315-6.
51.
Oram JF, Mendez AJ, Bierman E.HDL receptor function in cholesterol transport. In: Carlson LA, ed, Disorders of HDL. Selected proceedings . 1992Karolinska Hospital 50th Anniversary.
52.
Hunt SC, Hasstedt SJ, Kuida H., Stults BM, Hopkins PN, William RRGenetic heritability and common environmental components of resting and stressed blood pressures, lipids and body mass index in Utah pedigrees and twins. Am J Epidemiol1989;129:625-38.
53.
Watts GFCholesterol and coronary heart disease. Discovering the link. Curr Med LitLondon: 1990.
54.
Riesen WP, Mordasini M., Salzman C., Theter A., Gurtner HPApoproteins and lipids as discriminators of severity of coronary heart disease . Atherosclerosis1980;37-157-62.
Vigna GB, Bolzan M., Romagnoni F., et al. Lipids and other risk factors selected by discriminant analysis in symptomatic patients with supraaortic and peripheral atherosclerosis. Circulation1992;85:2205-11 .
57.
Kostner GM, Marth E., Pfeiffer KH, Wege H.Laboratory parameters as discriminators for peripheral atherosclerosis and stroke. Monogr Atheroscler1986;14:119-23.
58.
Schonfeld G. , George PK, Miller J., Reilly P., Witzum J.Apoproteins CII and CIII levels in hyperlipoproteinemia . Metabolism1979;28:1001-10.
59.
Dahlen G., Ericson C.A.new lipoprotein pattern in patients with angina pectoris. Scand J Clin Lab Invest1971;(suppl 118):54.
60.
Dahlen GH, Guyton JR, Arrar M., Farmer JA, Gotto AMAssociation of level for lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation1986;74:758-65.
61.
Rosengren A. , Wilhelmsen L., Eriksson E., Risberg B., Wedel H.Lipoprotein(a) and coronary heart disease: a prospective case control study in a general population sample of middle aged men. Br Med J1990;301:1248-51.
62.
Sandkamp M., Funke H., Schulte H., Kohler E., Assman G.Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age- Clin Chem1990;36:20-3.
63.
Nogues X., Senti M., Pedro-Botet M., et al. Enfermedad cardiaca coronaria y lipoproteina(a): su relation con ostros factores lipidicos de riesgo cardiovascular. Med Clin (Barcelona) 1992;98:171-4.
64.
Abe A., Noma A., Lee YJ, Yamaguchi H.Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis1992;96:9-15.
65.
Zenker G., Koltringer P.Bone G., Niederkom K., Pfeiffer K., Jurgens G.Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke1986;17:942-45.
66.
Murai A., Tanaka T., Miyahara T., Kameyama M.Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attack. Stroke1981 ;12:167-72.
67.
Woo J., Lau E., Lam Cwk, et al. Hypertension, lipoprotein(a), and apoprotein AI as risk factors for stroke in the Chinese. Stroke1991 ;22:203-8.
68.
Pedro-Botet J., Senti M., Nogues X., et al. Lipoprotein and apoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apoprotein E polymorphism. Stroke1992 ;23:1556-62.
69.
Norrgard O. , Angquist KA, Dahlen G.Lp(a) lipoprotein in patients with arterial insufficiency of the lower extremities. Eur J Vasc Surg1991;5:277-82.
70.
Nogues X., Senti M., Pedro-Botet J., Prat JR, Barraquer FVSerum lipoprotein(a) levels in men with peripheral vascular disease . Angiology1991;42:659-64.
71.
Pedro-Botet J., Senti M., Auguet T., et al. Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease. Atherosclerosis1993;104:87-94.
72.
Jelnes R., Gaardsting O., Jensen KH, Baegaard N., Tønnesen KHFate intermittent claudication: outcome and risk factors. Br Med J1986;293:1137-40.
73.
Kannel WB, Shurtleff D.Cigarettes and the development of intermittent claudication—the Framingham Study. Geriatrics1973;28:61-8.
74.
Hugson WG, Mann JI, Garrod A.Intermittent claudication: prevalence and risk factors. Br Med J1978;1:1379-81.
75.
US Department of Health and Human Services.The health consequences of smoking. A report of the Surgeon General. Bethesda: National Institutes of Health , 1983:182-6.
76.
O'Riordain DS, O'Donnell JARealistic expectations for the patients with intermittent claudication. Br J Surg1991;78: 861-3.
77.
Rooke TW, Osmundson J.The influence of age, sex, smoking, and diabetes on lower limb transcutaneous oxygen tension in patients with arterial occlusive disease. Arch Intern Med1990;150:129-32.
78.
Vogt MT, Cauley JA, Newmaa AB, Kulter LH, Hulley SBDecreased ankle/arm blood pressure index and mortality in elderly women. JAMA1993:270:465-9.
79.
Small M., Lowe Gdo, Beattie JM, Hutton IA, Lorimer R., Forbes CDSeverity of coronary artery disease and basal fibrinolysis. Haemostasis1987;17:305-11.
80.
Olofsson BO , Dahlen G., Nilsson TKEvidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease . Eur Heart J1989;10: 77-82.
Aznar J., Estelles A., Tormo G., et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J1988;59:535-41.
83.
Hamsten A., Wilman B., Faire U., Blomback M.Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med1985;313:1557-63.
84.
Almer LO, Ohlin H.Elevated levels of the rapid inhibitor of plasminogen activator (PAl-I) in acute myocardial infarction. Thromb Res1987 ;47:335-9.
85.
Catalano M.Perilli E., Carzaniga G., Carotta M., Lunghi N.Impact of mild Hypertriglyceridemia on fibrinolysis, Lp(a) and platelet activation indexes in mildly hypercholesterolemic patients . Int J Angiol (in press).
